Rhinosinusitis Without Polyposis

  • Abdullah Al-Bader
  • Roy R. Casiano
  • Lauren FineEmail author


There are more than 30 million cases of sinusitis annually in the United States, with direct cost of managing acute and chronic sinusitis exceeding $11 billion per year. Recurrent ARS (RARS) is defined as at least three or four or more annual episodes of ARS, with symptom-free periods in between episodes. For RARS, some investigations can be considered to rule out complications or to evaluate for other factors that may contribute to the development of or modify the management of this condition such as allergic or nonallergic rhinitis, asthma, cystic fibrosis, ciliary dyskinesia, and immunodeficiency. Chronic rhinitis affects upward of 70 million individuals in the United States making it one of the most prevalent medical disorders in the country and therefore the most common underlying condition associated with rhinosinusitis as a comorbidity. Therefore, it is essential to diagnose and treat chronic rhinitis correctly in order to prevent or reduce episodes of rhinosinusitis. In this chapter, we present a case of RARS and a case of chronic rhinitis complicated by rhinosinusitis followed by discussions including definitions, pathophysiology, diagnosis, and treatment options based on current guidelines.


Rhinitis Chronic rhinitis Nonallergic rhinitis Allergy Nasal obstruction Rhinorrhea Sinusitis Rhinosinusitis Rhinorrhea Recurrent acute rhinosinusitis 


  1. 1.
    Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Kumar KA, Kramper M, Orlandi RR, Palmer JN, Patel ZM, Peters A, Walsh SA, Corrigan MD. Clinical practice guideline (update): adult sinusitis executive summary. Otolaryngol Head Neck Surg. 2015;15:598–609.CrossRefGoogle Scholar
  2. 2.
    Van Loon JW, van Harn RP, Venekamp RP, Kaper NM, Sachs AP, Van der Heijden GJ. Limited evidence for effects of intranasal corticosteroids on symptom relief for recurrent acute rhinosinusitis. Otolaryngol Head Neck Surg. 2013;149:668–73.CrossRefPubMedGoogle Scholar
  3. 3.
    Orlandi RR, Kingdom TT, Hwang PH. International consensus statement on allergy and rhinology: rhinosinusitis executive summary. Int Forum Allergy Rhinol. 2016;6:S3–21.PubMedGoogle Scholar
  4. 4.
    Desrosiers M, Evans GA, Keith PK, Wright ED, Kaplan A, Bouchard J, Ciavarella A, Doyle PW, Javer AR, Leith ES, Mukherji A, Robert Schellenberg R, Small P, Witterick IJ. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2011;40:S99–193.PubMedGoogle Scholar
  5. 5.
    Peters AT, SS JH, Hamilos DL, Baroody F, Chandra RK, Grammar LC, Kennedy DW, Cohen NA, Kaliner MA, Wald ER, Karagianis A, Slavin RG. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol. 2014;113:347–85.CrossRefPubMedGoogle Scholar
  6. 6.
    Costa ML, Psaltis AJ, Nayak JV, Hwang PH. Medical therapy vs surgery for recurrent acute rhinosinusitis. Int Forum Allergy Rhinol. 2015;5:667–73.CrossRefPubMedGoogle Scholar
  7. 7.
    Loftus PA, Lin J, Tabaee A. Anatomic variants of the paranasal sinuses in patients with recurrent acute rhinosinusitis. Int Forum Allergy Rhinol. 2016;6:328–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Brook I, Frazier EH. Microbiology of recurrent acute rhinosinusitis. Laryngoscope. 2004;114:129–31.CrossRefPubMedGoogle Scholar
  9. 9.
    Kaper NM, Breukel L, Venekamp RP, Grolman W, Van der Heijden GJ. Absence of evidence for enhanced benefit of antibiotic therapy on recurrent acute rhinosinusitis episodes: a systematic review of the evidence base. Otolaryngol Head Neck Surg. 2013;149:664–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Bhattacharyya N. Surgical treatment of chronic recurrent rhinosinusitis: a preliminary report. Laryngoscope. 2006;116:1805–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Banov CH, Liberman P. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol. 2001;86:28–35.CrossRefGoogle Scholar
  12. 12.
    Hampel FCRP, Van Bavel J, Amar NJ, Daftary P, Wheeler W, Sacks H. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010;105:168–73.CrossRefGoogle Scholar
  13. 13.
    Greiwe JM, Jonathan A, Bernstein MD. Nonallergic rhinitis diagnosis. Immunol Allergy Clin N Am. 2016;36:289–303.CrossRefGoogle Scholar
  14. 14.
    Tran NP, Vickery J, Blaiss MS. Management of rhinitis: allergic and non-allergic. Allergy, Asthma Immunol Res. 2011;3:148–56.CrossRefGoogle Scholar
  15. 15.
    Becker S, Rasp J, Eder K, Berghaus A, Kramer MF, Groger M. Non-allergic rhinitis with eosinophilia syndrome is not associated with local production of specific IgE in nasal mucosa. Eur Arch Otorhinolaryngol. 2016;273:1469–75.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Scarupa MD, Kaliner MA. Nonallergic rhinitis, with a focus on vasomotor rhinitis clinical importance, differential diagnosis and effective treatment recommendations. World Allergy Organ J. 2009;2:20–5.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lieberman PL, Smith P. Nonallergic rhinitis: treatment. Immunol Allergy Clin N Am. 2016;36:305–19.CrossRefGoogle Scholar
  18. 18.
    Salib RJ, Harries PG, Nair SB, Howarth PH. Mechanisms and mediators of nasal symptoms in non-allergic rhinitis. Clin Exp Allergy. 2008;38:393–404.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Quillen DM, Feller DB. Diagnosing rhinitis: allergic vs nonallergic. Am Fam Physician. 2006;73:1583–90.Google Scholar
  20. 20.
    Greiner AN, Meltzer EO. Pharmacologic rationale for treating allergic and nonallergic rhinitis. J Allergy Clin Immunol. 2006;118:985–98.CrossRefPubMedGoogle Scholar
  21. 21.
    Petty DA, Blaiss MS. Intranasal corticosteroids topical characteristics: side effects, formulation and volume. Am J Rhinol Allergy. 2013;27:510–3.CrossRefPubMedGoogle Scholar
  22. 22.
    Sastre J, Mosqes R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22:1–12.PubMedGoogle Scholar
  23. 23.
    Namazy JA, Schatz M. The safety of intranasal steroids during pregnancy: a good start. J Allergy Clin Immunol. 2016;138:105–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Vaidyanathan S, Williamson P, Clearie K, Khan F, Lipworth B. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med. 2010;182:19–24.CrossRefGoogle Scholar
  25. 25.
    Singh U, Bernstein J. Intranasal capsaicin in management of nonallergic (vasomotor) rhinitis. Prog Drug Res. 2014;68:147–70.PubMedGoogle Scholar
  26. 26.
    Nguyen SA, Psaltis AJ, Schlosser RJ. Isotonic saline nasal irrigation is an effective adjunctive therapy to intranasal corticosteroid spray in allergic rhinitis. Am J Rhinol Allergy. 2014;28:308–11.CrossRefPubMedGoogle Scholar
  27. 27.
    Fokkens W, Hellings P, Segboer C. Capsaicin for rhinitis. Curr Allergy Asthma Rep. 2016;16(8):60.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Abdullah Al-Bader
    • 1
  • Roy R. Casiano
    • 1
  • Lauren Fine
    • 2
    Email author
  1. 1.Department of Otolaryngology-Head and Neck SurgeryUniversity of MiamiMiamiUSA
  2. 2.Division of Pulmonology, Department of Allergy, Critical Care and Sleep MedicineUniversity of MiamiMiamiUSA

Personalised recommendations